We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GE Healthcare Launches Cytiva™ Plus Cardiomyocytes
Product News

GE Healthcare Launches Cytiva™ Plus Cardiomyocytes

GE Healthcare Launches Cytiva™ Plus Cardiomyocytes
Product News

GE Healthcare Launches Cytiva™ Plus Cardiomyocytes


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "GE Healthcare Launches Cytiva™ Plus Cardiomyocytes"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Identifying potential cardiotoxicity as early as possible in the drug development process can reduce the risk of costly program failures and minimize health risks. Cytiva™ Plus provides a high fidelity human heart cell model that is available in quantities compatible with screening, enabling earlier and more confident prioritization of compounds.

Conveniently cryopreserved in quantities to match a range of applications, Cytiva Plus cardiomyocytes are ready-for-use in multi-electrode arrays, impedance and high content analysis applications for compound safety profiling.

The cardiomyocytes are produced in a way that reflects native human heart cell development, without engineering techniques that could alter expression levels of relevant genes. This makes Cytiva Plus a dependable and reproducible biologically relevant cell model that supports the measurement of electrophysiological, structural and functional cell changes, and demonstrates expected pharmacological responses to reference compounds.

Compatible with diverse detection platforms, Cytiva Plus enables compound profiling based on multiple cardiotoxicity indications for more integrated risk assessment and mechanistic investigations, enabling better safety prediction.

Advertisement